Screener
Bio-Rad Laboratories BIO Clinical Diagnostics — Cost of goods sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
FAQ
- What is Bio-Rad Laboratories's clinical diagnostics — cost of goods sold?
- Bio-Rad Laboratories (BIO) reported clinical diagnostics — cost of goods sold of $181.8M in Q1 2026.
- How has Bio-Rad Laboratories's clinical diagnostics — cost of goods sold changed year-over-year?
- Bio-Rad Laboratories's clinical diagnostics — cost of goods sold increased by 1.5% year-over-year, from $179.2M to $181.8M.
- What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — cost of goods sold?
- Over 3 years (2022 to 2025), Bio-Rad Laboratories's clinical diagnostics — cost of goods sold has grown at a 3.6% compound annual growth rate (CAGR), from $696.5M to $775.3M.
- What does clinical diagnostics — cost of goods sold mean?
- The direct costs attributable to the production and delivery of clinical diagnostic products, including raw materials, direct labor, and manufacturing overhead. It excludes operating expenses like R&D or SG&A.
Ask your AI about Bio-Rad Laboratories's clinical diagnostics — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude